HomeAI · summaries
Storia in 4 fonti
New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Anthropic deepens work with rare disease drugs
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
- ·
biopharmadive.com
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on…
